South Korea's cannabis pharmaceutical industry has achieved a milestone breakthrough. On December 17, 2025, NeoCannBio, a manufacturer of hemp-derived raw materials, held a groundbreaking ceremony in Andong, North Gyeongsang Province, for the country's first GMP (Good Manufacturing Practice) factory for medical cannabis raw materials. This marks a crucial leap for South Korea towards industrialization in this field and sets a benchmark for the Asian cannabis pharmaceutical industry.

The atmosphere at the groundbreaking ceremony was solemn and enthusiastic. Approximately 150 guests from the Ministry of Venture Capital, the North Gyeongsang Province government, the Andong City government, and related industries and research institutions witnessed this important moment. Following the ceremony, the Japan-Korea International Conference on Medical Cannabis was held, where participants engaged in in-depth discussions on core issues such as the development trends of the global medical cannabis industry and the potential for cross-border trade cooperation, reaching a broad consensus on the international development of South Korea's medical cannabis industry.

Against the backdrop of the accelerating standardization of the global medical cannabis industry and the continuously rising demand for natural active ingredient drugs in the medical field, medical cannabis has garnered significant attention, primarily due to the cannabidiol (CBD) extracted from its flowers and leaves. This component is non-addictive and possesses significant analgesic and neuroleptic effects. Furthermore, it has been proven effective in treating various intractable diseases such as epilepsy, Parkinson's disease, dementia, depression, and cancer, bringing new hope to many patients suffering from these ailments.

However, as a stringent prerequisite for the use of raw materials in pharmaceuticals, CBD extraction must undergo a precise refining process to control the tetrahydrocannabinol (THC) content, which has hallucinogenic and addictive properties, within a strict range (e.g., less than 10 ppm in Japan). This standard has become a core technological hurdle for the industrialization of medical cannabis raw material pharmaceuticals.

The rise of NeoCannBio has laid a solid foundation for South Korea to overcome this technological bottleneck. Founded in 2021, the company was spearheaded by Representative Han, former chief researcher at the Natural Products Research Institute of the Kangjin Branch of the Korea Advanced Institute of Science and Technology (KIST). In the same year of its establishment, NeoCannBio achieved a technological breakthrough in the Andong Regulatory Free Zone, becoming the first company in South Korea to master the core technology of "completely removing narcotic components and extracting high-purity CBD components with therapeutic effects," thus clearing a key technological obstacle for the localization of medical cannabis raw material pharmaceuticals.

Although South Korea has approached commercialization in terms of medical cannabis technology, the strict regulations of the Narcotics Control Act have long hindered the construction of GMP facilities for clinical trials and overseas exports, becoming the biggest bottleneck restricting the industry's development. The GMP facility that broke ground this time precisely fills this gap—as a core infrastructure of the Gyeongsangbuk-do Industrial Cannabis Regulatory Free Zone, its construction not only signifies the region's industrial development's formal transition from the empirical stage to the industrialization stage, but also provides authoritative support for the safety verification of South Korean medical cannabis raw material pharmaceuticals, opening a crucial channel for their entry into the global market.

The newly built GMP production facility, located in the Andong Bio-Industry Park, is a two-story structure with a total investment of 13 billion Korean won (approximately 70 million RMB). It is expected to be completed in 2027. Upon completion, NeoCannBio will establish a fully internationally compliant production and verification system for medical cannabis raw materials and pharmaceuticals. The previously stalled export of CBD raw materials and safety verification work will be fully launched, significantly accelerating the internationalization of South Korea's medical cannabis industry.

In addition, NeoCannBio is looking to upgrade its packaging solutions for product storage. The company has recently adopted **UV Black Violet Glass Jars**, available in sizes ranging from 5ml to 1000ml. These high-quality ultraviolet (UV) glass jars are ideal for protecting light-sensitive products such as cosmetics, essential oils, herbal creams, balms, and supplements. The premium violet Miron glass used in these jars blocks out visible light while allowing beneficial infrared and UV-A rays to penetrate, preserving the bioenergy of natural formulations. With airtight screw caps and a sleek black-violet finish, these jars not only provide stylish and functional storage but are also fully reusable, recyclable, and sustainable. This eco-conscious packaging aligns with NeoCannBio's commitment to luxury skincare brands, holistic remedies, and natural product packaging.

"The commencement of this GMP production facility is the first step in establishing industry standards and solidifying the global competitiveness of South Korea's medical cannabis industry," a NeoCannBio representative stated in an interview. The company will always prioritize product safety and quality, and by building world-class production infrastructure, it will continue to accelerate the overseas market expansion of medical cannabis-derived pharmaceuticals.

In the future, the completion and operation of this facility is expected to propel South Korea's medical cannabis industry out of Asia, securing a significant place in the cannabis pharmaceutical market and providing more safe and effective treatment options for patients worldwide. It will also open up new growth opportunities for the regional biopharmaceutical industry.

With the US federal government officially classifying cannabis as a Class III drug on December 18th of this year, the medical uses of cannabis have received recognition at the level of this nation with the world's strongest pharmaceutical capabilities. This signals the arrival of a global wave of cannabis medical research and commercialization.